Service d'Anatomie et Cytologie Pathologiques, CHU de Rennes, 35000 Rennes, France; Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, 35000 Rennes, France; UMR 6290 IGDR, Cancer du Rein-BIOSIT, Faculté de Médecine de Rennes, 35000 Rennes, France.
Service de Cytogénétique et Biologie Cellulaire, CHU de Rennes, 35000 Rennes, France; UMR 6290 IGDR, Cancer du Rein-BIOSIT, Faculté de Médecine de Rennes, 35000 Rennes, France.
Hum Pathol. 2014 Aug;45(8):1639-46. doi: 10.1016/j.humpath.2014.03.018. Epub 2014 Apr 18.
Clear cell renal cell carcinomas (ccRCCs) represent 70% of renal cancers, and several clinical and histolopathological factors are implicated in their prognosis. We recently demonstrated that the overexpression of PAR-3 protein encoded by the PARD3 gene could be implicated in renal oncogenesis. The object of this work was to study the association of intratumoral PAR-3 expression with known prognostic parameters and clinical outcome. In this aim, PAR-3 expression was assessed by immunohistochemistry in ccRCC tumors of 101 patients from 2003 to 2005. The immunostaining of PAR-3 was scored either as membranous (mPAR-3) or as both membranous and cytoplasmic (cPAR-3). Cytoplasmic PAR-3 was significantly associated with worse histopathological and clinical prognostic factors: Fuhrman grades 3 and 4, tumor necrosis, sarcomatoid component, adrenal invasion, renal and hilar fat invasion, eosinophilic component, a noninactivated VHL gene, higher tumor grade, lymph node involvement, metastasis, and worse clinical Eastern Cooperative Oncology Group and S classification scores. After multivariate analysis, 2 parameters were independently associated with cPAR-3: necrosis and eosinophilic components. In addition, cPAR-3 patients had shorter overall and progression-free survivals independently from strong prognostic validated factors like metastases. A cytoplasmic expression of PAR-3 is therefore implicated in worse clinical and pathological cancer features in ccRCC and could be useful to identify patients with high-risk tumors.
透明细胞肾细胞癌(ccRCC)占肾癌的 70%,多种临床和组织病理学因素与预后相关。我们最近证实,PARD3 基因编码的 PAR-3 蛋白的过表达可能与肾肿瘤发生有关。本研究的目的是研究肿瘤内 PAR-3 表达与已知预后参数和临床结果的关系。为此,我们在 2003 年至 2005 年间,对 101 名患者的 ccRCC 肿瘤进行了 PAR-3 免疫组化评估。PAR-3 免疫染色的评分分别为膜 PAR-3(mPAR-3)和膜及细胞质 PAR-3(cPAR-3)。细胞质 PAR-3 与较差的组织病理学和临床预后因素显著相关:Fuhrman 分级 3 和 4、肿瘤坏死、肉瘤样成分、肾上腺侵犯、肾和肾门脂肪侵犯、嗜酸性成分、非失活的 VHL 基因、更高的肿瘤分级、淋巴结受累、转移和较差的临床东部肿瘤协作组(ECOG)和 S 分类评分。多因素分析后,2 个参数与 cPAR-3 独立相关:坏死和嗜酸性成分。此外,cPAR-3 患者的总生存期和无进展生存期较短,独立于转移等经过验证的强预后因素。因此,cPAR-3 在 ccRCC 中与更差的临床和病理癌症特征相关,可用于识别高危肿瘤患者。